Printer Friendly

TARGET THERAPEUTICS TO BEGIN MARKETING FASTRACKER MICRO-CATHETER

 FREMONT, Calif., Aug. 25 /PRNewswire/ -- Target Therapeutics Inc. (NASDAQ: TGET) announced today that it will begin U.S. marketing of the FasTRACKER(TM), a new generation of Target micro-catheters. The FasTRACKER features a chemically bonded hydrophilic polymer that allows the micro-catheter to glide more easily through the circulatory system. In vitro testing demonstrated that the FasTRACKER reduced friction by more than 50 percent, compared with conventional catheters.
 Today's announcement was made following receipt of a 510(k) premarket notification from the U.S. Food and Drug Administration (FDA).
 As with the company's Tracker(R) micro-catheter products, the FasTRACKER incorporates innovative design characteristics including gradual transitioning of stiffness to provide a flexible, atraumatic distal portion and more rigid proximal segment for manipulation and advancement. The FasTRACKER also features a 2-micron-thick Hydrolene(TM) polymer that reduces friction when negotiating the torturous anatomy of the brain. As reference, red blood cells measure approximately 8 microns across, and the width of a human hair is approximately 40 microns.
 "One of the primary benefits of the FasTRACKER is that reduced friction will typically lead to reduced procedural time," according to Gary Bang, Target's president and chief executive officer. "Generally, the easier access available with this product will also allow interventional physicians to reach even more distant portions of the brain, facilitating treatment of deep arteriovenous malformations and aneurysms." Target's sales force will begin marketing the FasTRACKER immediately.
 Founded in 1985, Target Therapeutics Inc. develops, manufacturers and markets specialized disposable micro-catheters, guidewires, micro- coils and angioplasty products. These therapeutic devices are used in minimally invasive non-surgical procedures to reach disease sites throughout the body via the circulatory system. Target's products allow highly targeted treatment of the diseased, ruptured or blocked vessels of the brain responsible for stroke, as well as other disease sites in the body that are accessible through small blood vessels.
 -0- 8/25/93
 /CONTACT: analysts, Larry Tannenbaum, vice president of finance and administration and chief financial officer of Target Therapeutics, 510-440-7700; or media, Bruce Voss of Edelman Public Relations, 415-433-5381, for Target Therapeutics/
 (TGET)


CO: Target Therapeutics Inc. ST: California IN: MTC SU: PDT

TM-LH -- SF012 -- 5945 08/25/93 20:52 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 25, 1993
Words:361
Previous Article:DEJA SHOE UNVEILS NEWEST GENERATION OF FOOTWEAR MADE FROM RECYCLED MATERIALS AND PUSHES ENVIRONMENTAL SHOEMAKEING TO NEW HEIGHTS
Next Article:MTA BOARD APPROVES $3.3 BILLION FY 93-94 BUDGET
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters